

:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

RONALD A. SCHACHAR

U.S. Serial No.

09/556,143

Filing Date

April 21, 2000

Examiner

David M. Shay

Group Art Unit

3739

Title

SEGMENTED SCLERAL BAND FOR TREATMENT OF

PRESBYOPIA AND OTHER EYE DISORDERS

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

PETITION UNDER 37 C.F.R. § 1.144

Pursuant to 37 C.F.R. § 1.144, Applicant petitions from the pending restriction requirement entered March 24, 2003 in the above identified invention.

Restriction is only proper where the claims are independent or distinct. MPEP § 806. In passing on questions of restriction, the <u>claimed</u> subject matter must be compared in order to determine distinctness and independence. MPEP § 806.01.

The Restriction Requirement characterizes claims 45–46 as directed to an invention that is independent or distinct from the invention originally claimed "for the following reasons: the <u>apparatus</u> could be used for a substantially different method, such as transmyocardial revascularization." (Page 2, Office Action of March 24, 2003) (emphasis added).

DOCKET NO. PRES06-00163 SERIAL NO. 09/556,143 PATENT

Claims 45–46 are directed to a <u>method</u>, not to an apparatus as stated in the Office Action. In addition, each of claims 45–46 recite ablation or laser irradiation of the sclera and ciliary body/muscle of an <u>eye</u>. These structures play NO ROLE in "transmyocardial revascularization," which involves the <u>heart</u>. The arguments advanced by the Examiner are therefore completely baseless, and are arbitrary and capricious.

Applicant requests that the restriction requirement be withdrawn.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Davis Munck Deposit Account No. 50-0208.

Respectfully submitted,

DAVIS MUNCK, P.C.

Date: 1-29-03

Daniel E. Venglarik

Registration No. 39,409

P. O. Drawer 800889 Dallas, Texas 75380 (972) 628-3600 (voice) (972) 628-3616 (fax)

Email: dvenglarik@davismunck.com

Asserted "New Matter"

U.S. Patent 5,354,331

with the ray that strikes the atom; all the rays are in step, and the beam becomes bright enough to pass through the semisilvered mirror and leave the laser; the energy is as laser light.

of operating a laser in accordance with the principles of the present invention. The discussion of FIGURE 11 is made Turning to FIGURE 11, shown is an exemplary flow diagram (generally designated 1100) of an exemplary method concurrently with reference to FIGURE 10 and laser 1000. Exemplary method 1100 operates laser 1000 to treat This invention relates to methods of treating presbyopia, column 1, ocular hypertension.

presbyopia, hyperopia, primary open angle glaucoma and hyperopia, primary open angle glaucoma and ocular lines 7-12 these diseases by increasing the effective working distance of hypertension and more particularly to methods of treating the ciliary muscle.

Initially laser 1000 is enabled, causing laser beam generator 1020 to generate a laser beam whose intensity is controlled by controller 1030 (process step 1110). Laser 1000 is used to irradiate the sclera of an eye in the Alternatively the sclera in the region overlying the ciliary column 8, region of the ciliary body in accordance with the principles of body can be weakened by irradiation with a laser beam . . . muscle of the eye (Step 1120).

sclera with laser irradiation; (ii) ablating the sclera with laser thinned or weakened by the surgical removal of a portion of and 26-29 This step of irradiating the sclera of an eye in the

and to increase the effective working distance of the ciliary accommodation of the eye by increasing the effective lines 12-15 lines 26-28 the present invention to thereby weaken the sclera of the eye The invention also relates to increasing the amplitude of column 1, working range of the ciliary muscle.

region of the ciliary body may comprise (i) abrading the body may be weakened by surgical means. The sclera may be lines 3-12 Alternatively, the sclera in the region of the ciliary column 8,

Asserted "New Matter"

U.S. Patent 5,354,331

irradiation; (iii) incising the sclera with laser irradiation its collagenous substance, as, for example by ablating a (including at select angles); and (iv) decomposing partially portion of the thickness of the sclera. This thinning can be collagen fibers in the sclera.

accomplished by paring or by abrading the surface or by ablating the surface with laser irradiation. The sclera can also be weakened by incisions carefully placed at appropriate Alternatively the sclera in the region overlying the ciliary body can be weakened by irradiation with a laser beam to angles in the region overlying the ciliary body. . . decompose partially the collagen fibers

Any irradiative treatment with ionizing or nonarea adjacent to the ciliary body.

ionizing radiation that weakens the sclera may be used. For non-ionizing radiation that weakens the sclera may be used. lines 38-45 Any irradiative treatment with ionizing or column 8, example irradiation with electrons, protons, or x-rays and the For example irradiation with electrons, protons, or x-rays and like, or irradiation with ultrasonic waves or the like can be the like, or irradiation with ultrasonic waves or the like can be used. Thermal burning and/or scarring in the appropriate area used. Thermal burning and/or scarring in the appropriate area may also be used to induce an enlargement of the sclera in the may also be used to induce an enlargement of the sclera in the area adjacent to the ciliary body.